Citations

- 1. Mitochondrial Dysfunction in Alzheimer's Disease:
 - *Royea, J., et al.* (2017). "Angiotensin IV receptors mediate the cognitive and cerebrovascular benefits of losartan in a mouse model of Alzheimer's disease." *Journal of Neuroscience*, 37(23), 5562-5573.
 - *Serrano-Pozo, A., et al.* (2011). "Neuropathological alterations in Alzheimer's disease." *Cold Spring Harbor Perspectives in Medicine*, 1(1), a006189.
 - *Girouard, H., Iadecola, C.* (2006). "Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease." *Journal of Applied Physiology*, 100(1), 328-335.
- 2. Amyloid-Beta Pathology and Clearance:
 - *Wang, J., et al.* (2007). "Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease." *Journal of Clinical Investigation*, 117(11), 3393-3402.
 - *Lesné, S., et al.* (2006). "A specific amyloid-beta protein assembly in the brain impairs memory." *Nature*, 440(7082), 352-357.
 - *Holmes, C., et al.* (2008). "Long-term effects of Abeta42 immunization in Alzheimer's disease: Follow-up of a randomized, placebo-controlled phase I trial." *Lancet*, 372(9634), 216-223.

3. Neuroinflammation in Alzheimer's Disease:

- *McGeer, E. G., McGeer, P. L.* (2003). "Inflammatory processes in Alzheimer's disease." *Progress in Neuro-Psychopharmacology & Biological Psychiatry*, 27(5), 741-749.
- *Esposito, L., et al.* (2006). "Reduction in mitochondrial superoxide dismutase modulates Alzheimer's disease-like pathology and accelerates the onset of behavioral changes in human amyloid precursor protein transgenic mice." *Journal of Neuroscience*, 26(19), 5167-5179.
- *Park, L., et al.* (2005). "NADPH oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid beta-peptide." *Journal of Neuroscience*, 25(7), 1769-1777.

4. Angiotensin IV and AT Receptors:

- *Bosnyak, S., et al.* (2011). "Relative affinity of angiotensin peptides and novel ligands at AT1 and AT2 receptors." *Clinical Science*, 121(6), 297-303.
- *Chai, S. Y., et al.* (2000). "Distribution of angiotensin IV binding sites (AT4 receptor) in the human forebrain, midbrain, and pons as visualized by in vitro receptor autoradiography." *Journal of Chemical Neuroanatomy*, 20(3-4), 339-348.
- *Albiston, A. L., et al.* (2003). "AT4 receptor is insulin-regulated membrane aminopeptidase: Potential mechanisms of memory enhancement." *Trends in Endocrinology & Metabolism,* 14(2), 72-77.

- 5. Oxidative Stress and Mitochondrial Health:
 - Babior, B. M. (2004). "NADPH oxidase." Current Opinion in Immunology, 16(1), 42-47.
 - *Kundu, T. K., et al.* (2007). "Characterization of superoxide production from aldehyde oxidase: An important source of oxidants in biological tissues." *Archives of Biochemistry and Biophysics*, 460(1), 113-121.
 - *Park, L., et al.* (2011). "Scavenger receptor CD36 is essential for cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-beta." *Proceedings of the National Academy of Sciences of the USA*, 108(2), 5063-5068.
- 6. Anti-Inflammatory Therapies in Alzheimer's Disease:
 - *Minocycline* and its potential neuroprotective effects:
 - *Garrido-Mesa, N., et al.* (2013). "Minocycline: far beyond an antibiotic." *British Journal of Pharmacology*, 169(2), 337-352.
 - *Parachikova, A., et al.* (2010). "Minocycline ameliorates learning impairments and dendritic pathology in a mouse model of Alzheimer's disease." *Neurobiology of Disease*, 39(2), 166-176.

https://cosmicvibe.vgcats.com/

Scott Ramsoomair September 26, 2024